Public health and the knowledge industry;Saúde pública e indústria do conhecimento

Revista de Saude Publica

Volumn 43, Issue 6, 2009, Pages 1078-1083

  de Camargo Jr , Kenneth Rochel ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Health care sector; Knowledge; Publication bias; Scientific and technical publications; Scientific communication and diffusion; Scientific misconduct

Indexed keywords

ARTICLE; FINANCIAL MANAGEMENT; HUMAN; INDUSTRY; INFORMATION DISSEMINATION; KNOWLEDGE; PUBLIC HEALTH; PUBLISHING;

HUMANS; INDUSTRY; INFORMATION DISSEMINATION; KNOWLEDGE; MARKETING OF HEALTH SERVICES; PUBLIC HEALTH; PUBLISHING;

EID: 77951910078     PISSN: 00348910     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0034-89102009005000076     Document Type: Article

References (31)

1. Abramson J. Overdo$ed America: the broken promise of American medicine. New York: Harper Perennial; 2005.
2. Angell M. The truth about the drug companies: how they deceive us and what to do about it. New York: Random House; 2005.
3. Avorn J. Powerful medicines: the benefits, risks and costs of prescription drugs. New York: Vintage Books; 2005.
4. Baba A, Cook DM, McGarity TO, Bero LA. Legislating 'sound science': the role of the tobacco industry. Am J Public Health. 2005;95(Supl 1):20-7. DOI:10.2105/AJPH.2004.050963
5. Camargo Jr KR. The thought style of physicians: strategies for keeping up with medical knowledge. Soc Stud Sci. 2002;32(6):827-55. DOI:10.1177/030631270203200501
6. Camargo Jr K, Coeli CM. Theory in practice: why "good medicine" and "scientific medicine" are not necessarily the same thing. Adv Health Sci Educ Theory Pract. 2006;11(1):77-89. DOI:10.1007/s10459-005-6924-7
7. Chalmers I. From optimism to disillusion about commitment to transparency in the medico-industrial complex. J R Soc Med. 2006;99(7):337-41. DOI:10.1258/jrsm.99.7.337
8. Friedman LC, Daynard RA, Banthin CN. How tobacco-friendly science escapes scrutiny in the courtroom. Am J Public Health. 2005;95(Supl 1):16-20. DOI:10.2105/AJPH.2004.046227
9. Garfield E. How can impact factors be improved? BMJ. 1996;313(7054):411-3.
10. Goozner M. The $800 Million dollar pill: the truth behind the cost of new drugs. Berkeley: University of California Press; 2004.
11. Healy D. The latest mania: selling bipolar disorder. PLoS Med. 2006;3(4):185. DOI:10.1371/journal. pmed.0030185 rrsspp4433__66..iinnddbb 11008822 77//1122//22000099 1188::4488::5588 Rev Saúde Pública 2009;43(6):1078-83 1083
12. Kassirer J. The internet and the journal. N Engl J Med. 1995[cited 2007 Mar 27];332(25): 27-30. Available from: http://www.nejm.org/general/text/policies.pdf
13. Kassirer J, On the Take: How medicine's complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.
14. Kravitz RL, Epstein RM, Feldman MD, Franz CE, Azari R, Wilkes MS, et al. Influence of patient's requests for direct-to-consumer advertised antidepressants. JAMA. 2005;293(16):1995-2002. DOI:10.1001/jama.293.16.1995
15. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167-70. DOI:10.1136/bmj.326.7400.1167
16. Lexchin J. Bigger and Better: How Pfizer Redefined erectile dysfunction. PLoS Med. 2006;3(4):132. DOI:10.1371/journal.pmed.0030132
17. Michaels D, Monforton C. Manufacturing uncertainty: contested science and the protection of the public's health and environment. Am J Public Health. 2005;95 (Supl 1):39-48. DOI:10.2105/AJPH.2004.043059
18. Michaels D. Scientific evidence and public policy. Am J Public Health. 2005;95 (Supl 1):5-6. DOI:10.2105/AJPH.2005.065599
19. Neale AV, Schwartz KL, Bowman MA. Conflict of interest: can we minimize its influence in the biomedical literature? J Am Board Fam Med. 2005;18(5):411-3. DOI:10.3122/jabfm.18.5.411
20. Neff RA, Goldman LR. Regulatory parallels to Daubert: stakeholder influence, 'sound science', and the delayed adoption of health-protective standards. Am J Public Health. 2005;95(Supl 1):81-91. DOI:10.2105/AJPH.2004.044818
21. Reidy J. Hard Sell: the Evolution of a Viagra Salesman. Kansas City: Andrews McMeel Publishing; 2005.
22. Rest KM, Halpern MH. Politics and the erosion of federal scientific capacity: restoring scientific integrity to public health science. Am J Public Health. 2007;97 (11):1939-44. DOI:10.2105/AJPH.2007.118455
23. Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB. Evidence-Based Medicine: How to Practice & Teach EBM. Edinburgh: Churchill Livingstone; 1997.
24. Smith R. Unscientific Practice Flourishes in Science. BMJ. 1998;316(7137):1036.
25. Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med. 2005;2(5):138. DOI:10.1371/journal. pmed.0020138
26. Steinman MA, Bero LA, Chren MM, Landefeld CS. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006;145(4):284-93.
27. Tamber PS. Is scholarly publishing becoming a monopoly? BMC News Views. 2000;(1):1.
28. The National Institute for Health Care Management Research and Educational Foundation. Changing patterns of pharmaceutical innovation. Washington; 2002.
29. Tiefer L. Female sexual dysfunction: a case study of disease mongering and activist resistance. PLoS Med. 2006;3(4):178. DOI:10.1371/journal.pmed.0030178
30. Wagner W. The perils of relying on interested parties to evaluate scientific quality. Am J Public Health. 2005;95(Supl 1):99-106. DOI:10.2105/AJPH.2004.044792
31. Young C, Godlee F. Reed Elsevier's arms trade. BMJ. 2007;334(7593):547-8 DOI:10.1136/bmj.39153.580023.80